NOVARTIS FDA Approval NDA 022071

NDA 022071

NOVARTIS

FDA Drug Application

Application #022071

Documents

Letter2007-10-04
Letter2010-12-07
Letter2011-03-31
Letter2011-11-08
Letter2012-04-25
Letter2013-10-25
Label2011-04-01
Label2012-04-23
Review2009-03-12
Letter2013-06-18
Label2007-10-04
Label2010-12-04
Label2013-06-17
Label2013-10-25
Letter2016-08-23
Label2017-01-24
Letter2017-01-24
Pediatric Medical Review1900-01-01
Pediatric Clinical Pharmacology Review1900-01-01
Pediatric Statistical Review1900-01-01
Medication Guide2018-11-08
Label2019-04-01

Application Sponsors

NDA 022071NOVARTIS

Marketing Status

Discontinued001
Discontinued002

Application Products

001GRANULE;ORALEQ 125MG BASE/PACKET1LAMISILTERBINAFINE HYDROCHLORIDE
002GRANULE;ORALEQ 187.5MG BASE/PACKET1LAMISILTERBINAFINE HYDROCHLORIDE

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2007-09-28STANDARD
LABELING; LabelingSUPPL3AP2010-12-02UNKNOWN
LABELING; LabelingSUPPL4AP2011-03-30UNKNOWN
LABELING; LabelingSUPPL6AP2011-11-04STANDARD
LABELING; LabelingSUPPL7AP2012-04-23STANDARD
LABELING; LabelingSUPPL9AP2013-06-17STANDARD
LABELING; LabelingSUPPL10AP2013-10-23STANDARD
LABELING; LabelingSUPPL11AP2016-08-23STANDARD
LABELING; LabelingSUPPL13AP2017-01-19STANDARD
LABELING; LabelingSUPPL15AP2019-03-29STANDARD

Submissions Property Types

ORIG1Null8
SUPPL3Null7
SUPPL4Null7
SUPPL6Null7
SUPPL7Null31
SUPPL9Null7
SUPPL10Null15
SUPPL11Null6
SUPPL13Null15
SUPPL15Null31

CDER Filings

cder:Array
(
    [0] => Array
        (
            [ApplNo] => 22071
            [companyName] => 
            [docInserts] => ["",""]
            [products] => []
            [labels] => 
            [originalApprovals] => []
            [supplements] => 
            [actionDate] => 0000-00-00
        )

)

© 2026 FDA.report
This site is not affiliated with or endorsed by the FDA.